Population pharmacokinetics and exposure-response relationships of maribavir in transplant recipients with cytomegalovirus infection
{{output}}
Maribavir is approved for management of post-transplant cytomegalovirus (CMV) infections refractory and/or resistant to CMV therapies at a dose of 400 mg twice daily (BID). Population pharmacokinetic (PopPK) and exposure-response analyses were conducted to sup... ...
